It is with great pleasure that we announce the recruitment of the first patient in COMBACTE-CARE’s REJUVENATE study.
It is with great pleasure that we announce the recruitment of the first patients in COMBACTE-CARE’s REJUVENATE study. José Miguel Cisneros Herreros from the University Hospital Virgen del Rocio, Jesús Rodríguez-Baño and Luis Tallón's team from Hospital Universitario Virgen Macarena, enrolled the first patients on the 19th and 26th of May respectively.
Clinical Trials Centre Cologne (CTCC), of the University of Cologne was selected to act as an academic research organization (ARO) for the REJUVENATE study. COMBACTE-CARE’s REJUVENATE is the first study across the Innovative Medicines Initiative (IMI), New Drugs4Bad Bugs programme, with an academic partner ARO providing study operations.
COMBACTE-CARE, a project with 18 academic and 3 pharmaceutical partners, led by AstraZeneca as the coordinator and The University of Utrecht as the managing entity, aims to better understand the clinical management and outcomes of hospitalized patients with carbapenem resistant Enterobacteriaceae (CRE) infections, to analyse clinical and microbiological data to provide new insights for novel clinical trial designs, and to make recommendations for the development of novel antibiotics to treat resistant infections.
Seamus O'Brien, AstraZeneca EFPIA Coordinator
Number of sites
Number of cases started
Number of cases completed
Today was the first meeting to achieve this. The purpose of this new organization will be something like “To reduce the impact of infections on society”, and the vision will be something like “We make this possible by efficiently generating rigorous evidence for improved diagnostics, prevention and treatment of infections and to better respond to EID threats. This is facilitated by a European multidisciplinary clinical research network and innovative research approaches.” A long way to go, but the first steps have been set. We will keep you posted.
Marc Bonten, UMC Utrecht, Academic Coordinator
The main goal of the meeting is to move beyond discussions and identify key policies that can be implemented globally to both stimulate the innovation of critically-needed new treatments and ensure their availability and sustainable use. A smaller policy meeting the next day will capitalize on the presence of key high-level policy-makers and stakeholders that have attended the DRIVE-AB conference on 2 June and will build on those discussions. This follow-up meeting will focus on DRIVE-AB’s preliminary work on new economic models, share DRIVE-AB’s preliminary technical analysis of the models currently identified as most promising and receive feedback, identify implementation challenges and knowledge gaps, and develop a roadmap for the remaining 18 months of the project. Input from the conference and the policy meeting will help inform DRIVE AB’s policy recommendations to the European Commission.
Read more on DRIVE-AB.